PT1474416E - Derivados di-hidrobenzodiazepin-2-ona para o tratamento de perturbações neurológicas - Google Patents

Derivados di-hidrobenzodiazepin-2-ona para o tratamento de perturbações neurológicas Download PDF

Info

Publication number
PT1474416E
PT1474416E PT03702549T PT03702549T PT1474416E PT 1474416 E PT1474416 E PT 1474416E PT 03702549 T PT03702549 T PT 03702549T PT 03702549 T PT03702549 T PT 03702549T PT 1474416 E PT1474416 E PT 1474416E
Authority
PT
Portugal
Prior art keywords
phenyl
pyridin
mmol
trifluoromethyl
methyl
Prior art date
Application number
PT03702549T
Other languages
English (en)
Portuguese (pt)
Inventor
Geo Adam
Erwin Goetschi
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PT1474416E publication Critical patent/PT1474416E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT03702549T 2002-02-06 2003-01-28 Derivados di-hidrobenzodiazepin-2-ona para o tratamento de perturbações neurológicas PT1474416E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02002012 2002-02-06

Publications (1)

Publication Number Publication Date
PT1474416E true PT1474416E (pt) 2007-12-27

Family

ID=27675598

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03702549T PT1474416E (pt) 2002-02-06 2003-01-28 Derivados di-hidrobenzodiazepin-2-ona para o tratamento de perturbações neurológicas

Country Status (30)

Country Link
US (1) US6949542B2 (enExample)
EP (1) EP1474416B1 (enExample)
JP (1) JP4077411B2 (enExample)
KR (1) KR20040081486A (enExample)
CN (1) CN100497333C (enExample)
AR (1) AR038481A1 (enExample)
AT (1) ATE374196T1 (enExample)
AU (1) AU2003205695B8 (enExample)
BR (1) BR0307474A (enExample)
CA (1) CA2474219C (enExample)
DE (1) DE60316538T2 (enExample)
DK (1) DK1474416T3 (enExample)
ES (1) ES2294264T3 (enExample)
GT (1) GT200300028A (enExample)
HR (1) HRP20040678A2 (enExample)
IL (1) IL163102A (enExample)
MX (1) MXPA04007516A (enExample)
MY (1) MY176608A (enExample)
NO (1) NO327697B1 (enExample)
NZ (1) NZ534122A (enExample)
PA (1) PA8565901A1 (enExample)
PE (1) PE20031011A1 (enExample)
PL (1) PL372425A1 (enExample)
PT (1) PT1474416E (enExample)
RU (1) RU2315764C2 (enExample)
SI (1) SI1474416T1 (enExample)
TW (1) TWI326599B (enExample)
UY (1) UY27654A1 (enExample)
WO (1) WO2003066623A1 (enExample)
ZA (1) ZA200406032B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU779874B2 (en) 1999-10-15 2005-02-17 F. Hoffmann-La Roche Ag Benzodiazepine derivatives
PL1651234T3 (pl) * 2003-07-25 2008-02-29 Hoffmann La Roche Kompozycja antagonisty mGluR2 i inhibitora AChE do leczenia ostrych i/lub przewlekłych zaburzeń neurologicznych
ATE463495T1 (de) * 2005-09-27 2010-04-15 Hoffmann La Roche Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
MX2009010729A (es) * 2007-04-19 2009-10-26 Hoffmann La Roche Derivados de dihidro-benzo[b] [1,4]diazepin-2-ona-sulfonamida.
JP5204232B2 (ja) 2007-08-27 2013-06-05 エフ.ホフマン−ラ ロシュ アーゲー Fxrアゴニストとして使用されるベンゾイミダゾール誘導体
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
BRPI0816970A2 (pt) 2007-09-14 2015-03-24 Ortho Mcneil Janssen Pharm 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
CA2704436C (en) 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI0916576A2 (pt) 2008-08-04 2017-06-27 Chdi Inc pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としての3−アザビシクロ[3.1.0]ヘキシル誘導体
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
TWI481601B (zh) 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物
WO2011021676A1 (ja) 2009-08-21 2011-02-24 大塚製薬株式会社 ベンゾ[b][1,4]ジアゼピン-2,4-ジオン化合物の製造方法
NZ601547A (en) 2010-01-25 2014-04-30 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
WO2012149540A1 (en) 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
US9193710B2 (en) 2011-08-29 2015-11-24 Sanford-Burnham Medical Research Institute Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
SG2014012926A (en) 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013033068A1 (en) 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2877444B1 (en) 2012-07-27 2020-09-02 The Broad Institute, Inc. Inhibitors of histone deacetylase
HK1206615A1 (en) 2012-10-23 2016-01-15 霍夫曼-拉罗奇有限公司 Mglu2/3 antagonists for the treatment of autistic disorders
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
MX2016013711A (es) 2014-04-23 2017-01-13 Hoffmann La Roche Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales.
US9969726B2 (en) 2014-06-10 2018-05-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof
MX372995B (es) 2014-07-17 2020-04-13 Chdi Foundation Inc Metodos y composiciones para el tratamiento de trastornos relacionados con vih.
JP2017206438A (ja) * 2014-08-22 2017-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロイミダゾ[1,5−d][1,4]オキサゼピン化合物(TETRAHYDROIMIDAZO[1,5−d][1,4]OXAZEPINECOMPOUND)
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CA3125731A1 (en) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE105839T1 (de) * 1989-03-23 1994-06-15 Pfizer Antiallergische mittel auf der basis von diazepin.
TR200201023T2 (tr) 1999-10-15 2002-09-23 F. Hoffmann-La Roche Ag Benzodiazepin türevleri.
AU779874B2 (en) 1999-10-15 2005-02-17 F. Hoffmann-La Roche Ag Benzodiazepine derivatives

Also Published As

Publication number Publication date
SI1474416T1 (sl) 2008-02-29
HK1078858A1 (zh) 2006-03-24
AU2003205695B2 (en) 2008-04-03
CN100497333C (zh) 2009-06-10
EP1474416B1 (en) 2007-09-26
KR20040081486A (ko) 2004-09-21
AU2003205695A1 (en) 2003-09-02
WO2003066623A1 (en) 2003-08-14
NO327697B1 (no) 2009-09-14
MY176608A (en) 2020-08-18
AR038481A1 (es) 2005-01-19
HRP20040678A2 (en) 2005-10-31
TW200302730A (en) 2003-08-16
BR0307474A (pt) 2004-11-09
AU2003205695B8 (en) 2008-05-01
CA2474219C (en) 2010-04-13
MXPA04007516A (es) 2004-11-10
PL372425A1 (en) 2005-07-25
ZA200406032B (en) 2005-10-12
NZ534122A (en) 2006-12-22
RU2004126945A (ru) 2005-06-27
ES2294264T3 (es) 2008-04-01
NO20043237L (no) 2004-08-02
TWI326599B (en) 2010-07-01
PE20031011A1 (es) 2003-11-29
IL163102A (en) 2011-07-31
RU2315764C2 (ru) 2008-01-27
UY27654A1 (es) 2003-08-29
JP2005522440A (ja) 2005-07-28
DE60316538T2 (de) 2008-08-21
US6949542B2 (en) 2005-09-27
DK1474416T3 (da) 2008-01-14
US20030166639A1 (en) 2003-09-04
PA8565901A1 (es) 2003-09-05
DE60316538D1 (de) 2007-11-08
ATE374196T1 (de) 2007-10-15
CA2474219A1 (en) 2003-08-14
GT200300028A (es) 2004-06-11
CN1633430A (zh) 2005-06-29
EP1474416A1 (en) 2004-11-10
JP4077411B2 (ja) 2008-04-16

Similar Documents

Publication Publication Date Title
ES2294264T3 (es) Derivados de hidrobenzodiazepin-2-ona para el tratamiento de transtornos neurologicos.
KR100566171B1 (ko) mGluR2 길항제 Ⅱ인디하이드로-벤조[b][1,4]디아제핀-2-온 유도체
JP4043953B2 (ja) mGluR2アンタゴニストIとしてのジヒドロ−ベンゾ〔b〕〔1,4〕ジアゼピン−2−オン誘導体
AU2002312788A1 (en) Dihydro-benzo [b] [1, 4] diazepin-2-one derivatives as mGluR2 antagonists II
AU2002310912A1 (en) Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mGluR2 antagonists I
HK1078858B (en) Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders